title: [Efficacy and Security of Intrathecal with Methotrexate in the Treatment of Meningeal Carcinomatosis].
abstract: BACKGROUND
  Leptomeningeal carcinomatosis is a rare type of metastatic tumors of the central nervous system. In recent years, with the improvement of neoplasms therapies and longer survival of patients by better systemic control, incidence of leptomeningeal metastases has increased every year. However, there is still lack of effective therapies. The aim of this study is to investigate the efficacy, security and prognosis of intrathecal chemotherapy with methotrexate (MTX) in the treatment of neoplastic meningitis.
  
  
  METHODS
  A total of 27 patients were enrolled. We investigated clinical features and cerebrospinal fluid (CSF) examination results retrospectively, and analyzed the adverse reactions as well as prognosis after intrathecal chemotherapy.
  
  
  RESULTS
  All 27 patients were treated by intrathecal MTX, 70.4% had clinical remission, however, there was no significant difference in CSF pressure and CSF biochemical changes. We observed that 55.6% patients were all appropriate, 25.9% appeared lower limb numbness and mild pain, no serious irreversible adverse reactions occurred. Median overall survival was 4 months.
  
  
  CONCLUSIONS
  We suggest that intrathecal administration of MTX is associated with improvement of symptoms of leptomeningeal metastasis patients and no severe adverse events observed.
authors.affiliation: General Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Wu
authors.affiliation: Internal Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.affiliation: Radiotherapy Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Jianping
authors.initials: J
authors.lastname: Xiao
authors.affiliation: General Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Boyan
authors.initials: B
authors.lastname: Yang
authors.affiliation: General Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Yu
authors.affiliation: General Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Wu
authors.affiliation: Neurosurgery Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Jinghai
authors.initials: J
authors.lastname: Wan
authors.affiliation: General Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Xu
authors.affiliation: Neurosurgery Department,  Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
authors.forename: Jianxin
authors.initials: J
authors.lastname: Kong
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D055756:Meningeal Carcinomatosis / Q000188:drug therapy* / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009423:Nervous System Neoplasms / Q000188:drug therapy* / Q000556:secondary; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D008727:Methotrexate